Taking a step back to consider long-term treatment options in adult ITP

Sponsored by Novartis Pharmaceuticals Australia Pty Ltd

Clinicians need to take time out to consider other approaches to the long-term management of primary immune thrombocytopenia (ITP) in patients not adequately responding to first-line therapy, according to haematologist Danny Hsu from the Liverpool hospital in New South Wales. “For patients without a sustained and consistent response on first-line therapy, it’s important to take ...

Already a member?

Login to keep reading.

© 2021 the limbic